Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome
NCT00965835 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2009-12-29
Summary
The purpose of this study is to develop small molecule radio-labeled probes of beta-amyloid, to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease (AD). The study hypothesis is that PET imaging of small molecule probes, in the form of novel fluorescent dyes with radioactive labels, will demonstrate cerebral patterns in patients with AD that are distinct from those of age-matched persons who are cognitively intact.
Conditions
- Down Syndrome
- Alzheimer's Disease
Sponsors & Collaborators
-
National Institute on Aging (NIA)
lead NIH
Principal Investigators
-
Linda Nelson, PhD · Semel Institute, UCLA
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-08-31
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
Countries
- United States
Study Locations
More Related Trials
-
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
NCT02759887 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography of Amyloid in Alzheimer's Disease
NCT00205621 ·Status: SUSPENDED ·Phase: PHASE1
-
Imaging of Brain Amyloid Plaques in the Aging Population
NCT00950430 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Serotonin and Amyloidopathy
NCT02895932 ·Status: COMPLETED ·Phase: NA
-
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
NCT02317250 ·Status: WITHDRAWN ·Phase: PHASE3
-
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
NCT02740634 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Imaging Tau Deposition in the Brain of Elderly Subjects
NCT02958670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans
NCT03287765 ·Status: COMPLETED
-
Imaging Tau in Alzheimer's Disease and Normal Aging
NCT03373604 ·Status: COMPLETED ·Phase: PHASE2
-
PET Changes in Alzheimer's Disease (AD)
NCT00094913 ·Status: UNKNOWN
-
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
NCT00657813 ·Status: TERMINATED ·Phase: PHASE1
-
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259 ·Status: COMPLETED ·Phase: PHASE2
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·Status: RECRUITING ·Phase: PHASE3
-
Tau PET Outcomes With Anti-amyloid Immunotherapies
NCT06723015 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Imaging Biomarkers in Preclinical and Symptomatic AD
NCT04134923 ·Status: RECRUITING
-
New Biomarker for Alzheimer's Disease Diagnostic
NCT01315639 ·Status: COMPLETED ·Phase: NA
-
Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
NCT06402370 ·Status: RECRUITING
-
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
NCT02531360 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)
NCT06467981 ·Status: COMPLETED
-
Eye to Brain Connection
NCT05215782 ·Status: COMPLETED
-
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598 ·Status: RECRUITING
-
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
NCT00287248 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
NCT03058965 ·Status: COMPLETED ·Phase: EARLY_PHASE1